April W. Armstrong

1 month ago | dermatologytimes.com | Kaitlyn Bader |April W. Armstrong

Author(s):,April Armstrong, MD, MPH, FAAD, discusses her late-breaking presentation at AAD on the treatment response in patients with moderate to severe chronic CHE treated with delgocitinib. “About a quarter of the patients have achieved either significant improvement in their pain or itch score, or maintained at least 75% improvement in their severity through not only at week 16, but also in the weeks prior to week 16.

2 months ago | jamanetwork.com | Joel M. Gelfand |April W. Armstrong |Henry W. Lim |Steven Feldman

Errors in Abstract, Results, and Table 1 Home- vs Office-Based Narrowband UV-B Phototherapy for Patients With Psoriasis Joel M. Gelfand, MD; April W. Armstrong, MD; Henry W. Lim, MD; Steven R. Feldman, MD, PhD; Sandra M. Johnson, MD; W. C. Cole Claiborne, MD; Robert E. Kalb, MD; Jeannette Jakus, MD; Aaron R. Mangold, MD; R. Hal Flowers, MD; Tina Bhutani, MD; John R. Durkin, MD; Jerry Bagel, MD; Scott Fretzin, MD; Michael P.

Nov 27, 2024 | jamanetwork.com | April W. Armstrong |Mark Lebwohl |Richard Warren |Howard Sofen

Key PointsQuestion  What is the safety and efficacy of continuous treatment with deucravacitinib over a 3-year period? Findings  In this integrated analysis of the phase 3 POETYK PSO-1, PSO-2, and nonrandomized long-term extension trials in 1519 patients with moderate to severe plaque psoriasis treated through 3 years with 1 or more doses of deucravacitinib, no new safety signals were observed compared with the first year.

Nov 7, 2024 | emjreviews.com | Melinda Gooderham |Marjolein de Bruin-Weller |April W. Armstrong

While for some individuals with atopic dermatitis (AD), the disease can be controlled with topical treatments, those with moderate-to-severe AD often require systemic therapy for long-term disease control. Systemic treatments for AD include conventional systemic agents, small molecule inhibitors, and biologics, each with its own risks and benefits. For example, conventional systemic agents carry significant risks with long-term use, and small molecule inhibitors require frequent dosing.

Sep 13, 2024 | dermatologytimes.com | Maddi Hebebrand |April W. Armstrong

September 13, 2024By Armstrong shared insights on the recently released NPF psoriasis health indicator report including pearls on national health data and unmet needs in public health campaigns.